Patients should contact their GP or diabetes team if they experience any unusual symptoms, particularly abdominal pain, skin changes, joint pain, or signs of infection
Elevated hsCRP is an independent cardiovascular risk factor, and its reduction is considered a surrogate marker for improved cardiovascular outcomes Systolic blood pressure clinically meaningful reductions These improvements are consistent with but in several cases exceed the cardiometabolic benefits observed with semaglutide and tirzepatide in their respective Phase III programs
Those taking GIP/GLP-1 dual agonists, such as Zepbound (Tirzepatide), have shown even greater results
Decreased carnitine levels may contribute to the development of thyroid myopathy [79], and carnitine therapy can effectively reduce muscle function damage caused by hyperthyroidism
Keller, J., Beglinger, C., Holst, J